RxSight (RXST) grows LAL volume but posts wider 2025 loss, soft 2026 outlook

Rhea-AI Filing Summary

RxSight, Inc. reported mixed fourth quarter and full-year 2025 results, highlighted by strong adoption of its Light Adjustable Lens (LAL) but weaker Light Delivery Device (LDD) sales. Full-year revenue was $134.5 million, down 4% from 2024, as 12% LAL growth was offset by a 48% drop in LDD system sales.

Gross profit for 2025 rose to $103.0 million, with margin improving to 76.6% from 70.7%, driven by a higher mix of LAL revenue. Operating expenses increased 11% to $151.2 million, reflecting commercial expansion, R&D and marketing, leading to a wider net loss of $38.9 million, or $(0.95) per share. Adjusted net loss was $7.3 million, or $(0.18) per share.

In Q4 2025, revenue was $32.6 million, down 19% year over year, with LAL revenue down 1% and LDD revenue down 72% after record placements in the prior year quarter. Q4 gross margin improved to 77.5%, while net loss was $9.2 million. The company ended 2025 with $228.1 million in cash, cash equivalents and short-term investments and an installed base of 1,134 LDDs supporting 109,615 LAL units sold in 2025.

For 2026, RxSight guided to revenue of $120.0–$135.0 million, gross margin of 70%–72%, operating expenses of $150.0–$160.0 million, and non-cash stock-based compensation of $30.0–$32.0 million, reflecting expectations for lower LDD placements and higher per-unit manufacturing costs.

Insights

Medical devices equity analyst

LAL adoption and margins improved, but device sales and losses weigh on results.

RxSight showed clear traction in its core Light Adjustable Lens business in 2025, with LAL unit sales up 12% to 109,615 and gross margin expanding to 76.6%. This reflects a healthier mix toward recurring lens revenue, which is often more durable than capital equipment sales.

However, total revenue fell 4% to $134.5 million as Light Delivery Device sales dropped 48%, and operating expenses grew 11% to support commercial expansion and R&D. That pushed net loss to $38.9 million, widening from 2024, even though adjusted net loss remained much smaller at $7.3 million.

The 2026 outlook, with revenue of $120.0–$135.0 million and gross margin of 70%–72%, implies pressure from lower LDD production and higher per-unit costs. With cash, cash equivalents and short-term investments of $228.1 million as of December 31, 2025, the company appears funded to pursue its strategy while future filings detail how LAL procedure growth tracks against this guidance.

false000111148500011114852026-02-252026-02-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 25, 2026

RxSight, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40690	94-3268801
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California				92656
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (949) 521-7830

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		RXST		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On February 25, 2026, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three and twelve months ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

The following exhibit is furnished as part of this report:

Exhibit number		Description
99.1		Press Release dated February 25, 2026.
104		Cover Page Interactive Data File (embedded within the inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			RxSight, Inc.
Date:	February 25, 2026	By:	/s/ Mark Wilterding
			Name: Mark Wilterding Title: Chief Financial Officer

Exhibit 99.1

RXSIGHT, INC. REPORTS FOURTH QUARTER AND 2025 RESULTS; ISSUES 2026 GUIDANCE

Aliso Viejo, Calif. – February 25, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter and full year ended December 31, 2025.

Strategic Highlights and Recent Developments

•2025 Light Adjustable Lens (LAL® and LAL+®) unit sales increased 12% to 109,615

•Over 300,000 RxSight LAL procedures performed since launch, reinforcing the benefits of post-operative adjustability in clinical practice

•Light Delivery Devices (LDD™) installed base expanded to 1,134, providing a strong foundation for future procedure growth

•RxSight’s FDA Post-approval study results, demonstrating statistically superior outcomes for LAL eyes compared to historical results from contemporary toric IOLs, were accepted for publication in the Journal of Cataract & Refractive Surgery

•Regulatory approval received in Australia, expanding the company’s addressable international opportunity

“Based on our fourth quarter results, we believe that the commercial initiatives implemented in the second half of 2025 are showing early signs of progress,” said Ron Kurtz, President and Chief Executive Officer of RxSight. “While there is still more work ahead, full year LAL growth reflected strong adoption as physicians and patients recognize the value of the company’s differentiated therapy. Our team remains committed to driving the disciplined execution that supports doctors as they deliver the benefits of high-quality customized vision to their patients.”

Fiscal Year 2025 Financial Results

Full-year 2025 global sales of $134.5 million decreased 4% versus the prior year. LAL revenue growth of 12% was offset by a 48% decrease in LDD system sales compared to 2024.

2025 gross profit was $103.0 million, or 76.6% of revenue compared to gross profit of $98.9 million, or 70.7% of revenue in 2024. The increase in gross margin was primarily due to a greater percentage of revenue from LAL sales.

Operating expenses for 2025 were $151.2 million, an 11% increase compared to $135.8 million in 2024. The increase was driven primarily by strategic investments to support our expanding commercial and operational footprint, in addition to research and development and marketing activities. The company is building international infrastructure and maintains regulatory approvals for the RxSight system in North America, Europe, Singapore, South Korea and, most recently, Australia.

In 2025, net loss was $(38.9) million, or $(0.95) per share on a basic and diluted basis compared to a net loss of $(27.5) million, or $(0.71) per share on a basic and diluted basis in 2024. Adjusted net loss was $(7.3) million, or $(0.18) per share on a basic and diluted basis, in 2025, compared to an adjusted net loss of $(2.8) million, or $(0.07) per share on a basic and diluted basis in 2024.

As of December 31, 2025, cash, cash equivalents and short-term investments totaled $228.1 million.

Fourth Quarter Financial Results

In the fourth quarter of 2025, total revenue was $32.6 million, a decrease of 19% compared to $40.2 million in the fourth quarter of 2024, largely reflecting lower LDD revenue compared to record LDD placements in the prior year period. For the quarter, LAL revenue decreased 1% year over year, while LDD revenue decreased 72%. Sequential LAL procedure growth reflects steady activity across the installed base, supported in part by recent commercial initiatives and typical seasonal trends.

Fourth quarter gross profit was $25.3 million or 77.5% of revenue, a decrease of $3.5 million compared to gross profit of $28.8 million or 71.6% of revenue for the year-ago period. The increase in gross profit as percent of revenue was primarily driven by the favorable shift in product mix toward LAL sales.

Total operating expenses were $36.6 million, a 2% decrease from $37.4 million in the year-ago period. The decrease was driven by lower personnel costs, partially offset by continued investments to support LAL sales and advance the company’s research and development pipeline.

In the fourth quarter of 2025, the company reported a net loss of $(9.2) million, or $(0.22) per basic and diluted share, compared to a net loss of $(5.9) million, or $(0.15) per basic and diluted share in the fourth quarter of 2024. Adjusted net loss in the fourth quarter of 2025 was $(1.3) million, or $(0.03) per basic and diluted share, compared to an adjusted net gain of $1.3 million, or $0.03 per basic and diluted share in the fourth quarter of 2024.

Unit Sales Summary

Product	2025 Units Sold	YoY Change vs. 2024	Q4 2025 Units Sold	YoY Change vs. Q4 2024	QoQ Change vs. Q3 2025
Light Adjustable Lenses	109,615	+12%	28,611	(2%)	+10%
Light Delivery Devices	163	(47%)	25	(70%)	0%

2026 Guidance

The company provided its full year 2026 financial guidance as follows:

•Revenue of $120.0 to $135.0 million, reflecting lower year-over-year LDD placements;

•Gross margin of 70% to 72%, driven by higher per-unit manufacturing costs associated with lower LDD production volumes;

•Operating expenses of $150.0 million to $160.0 million; and

•Non-cash stock-based compensation expense of $30.0 million to $32.0 million.

Conference Call

On Wednesday, February 25, 2026, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its fourth quarter and full year 2025 financial results. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 3406720. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Forward-Looking Statements

This press release contains forward-looking statements, including: statements regarding the company’s expectations that commercial initiatives implemented in the second half of 2025 are showing early signs of progress; statements relating to 2025 LAL growth and adoption trends in the United States; and statements concerning the company’s commitment to disciplined execution in support of physicians delivering customized vision solutions to their patients. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other same terminology. These statements are only predictions based on

our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part I, Item 1A (Risk Factors) in the Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (SEC) on or about the date hereof, and the other documents that RxSight may file from time to time with the SEC. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

Investor Relations Contact:

Oliver Moravcevic

VP, Investor Relations

omoravcevic@rxsight.com

RxSight, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE LOSS (UNAUDITED)

(In thousands, except share and per share amounts)

		Three Months Ended December 31,								Year Ended December 31,
		2025				2024				2025				2024
Sales		$	32,607			$	40,214			$	134,479			$	139,927
Cost of sales			7,344				11,426				31,470				40,984
Gross profit			25,263				28,788				103,009				98,943
Operating expenses:
Selling, general and administrative			27,694				28,209				112,651				101,434
Research and development			8,905				9,208				38,549				34,367
Total operating expenses			36,599				37,417				151,200				135,801
Loss from operations			(11,336	)			(8,629	)			(48,191	)			(36,858	)
Other income (expense), net:
Interest expense			(4	)			(5	)			(19	)			(21	)
Interest and other income			2,195				2,708				9,332				9,474
Loss before income taxes			(9,145	)			(5,926	)			(38,878	)			(27,405	)
Income tax expense			6				12				66				50
Net loss		$	(9,151	)		$	(5,938	)		$	(38,944	)		$	(27,455	)
Other comprehensive (loss) income
Unrealized (loss) gain on short-term investments			(13	)			(344	)			(136	)			180
Foreign currency translation gain (loss)			5				(12	)			23				(9	)
Total other comprehensive (loss) income			(8	)			(356	)			(113	)			171
Comprehensive loss		$	(9,159	)		$	(6,294	)		$	(39,057	)		$	(27,284	)
Net loss per share:
Basic and diluted		$	(0.22	)		$	(0.15	)		$	(0.95	)		$	(0.71	)
Weighted-average shares used in computing net loss per share:
Attributable to common stock, basic and diluted			41,175,725				40,356,756				40,850,739				38,867,726

RxSight, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(In thousands, except share and per share amounts)

		December 31,				December 31,
		2025				2024
Assets
Current assets:
Cash and cash equivalents		$	19,949			$	16,706
Short-term investments			208,179				220,517
Accounts receivable			23,383				30,050
Inventories, net			31,559				22,009
Prepaid and other current assets			4,389				4,541
Total current assets			287,459				293,823
Property and equipment, net			13,056				12,413
Operating leases right-of-use assets			9,959				11,217
Restricted cash			750				750
Other assets			590				360
Total assets		$	311,814			$	318,563
Liabilities and stockholders' equity
Current liabilities:
Accounts payable		$	5,296			$	4,544
Accrued expenses and other current liabilities			19,795				20,358
Lease liabilities			1,162				974
Total current liabilities			26,253				25,876
Long-term lease liabilities			9,878				11,322
Other long-term liabilities			—				127
Total liabilities			36,131				37,325
Commitments and contingencies
Stockholders' equity:
Common stock, $0.001 par value, 900,000,000 shares authorized,  41,242,005 shares issued and outstanding as of December 31, 2025 and   40,428,220 shares issued and outstanding as of December 31, 2024			41				40
Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued   and outstanding			—				—
Additional paid-in capital			936,628				903,127
Accumulated other comprehensive loss			53				166
Accumulated deficit			(661,039	)			(622,095	)
Total stockholders' equity			275,683				281,238
Total liabilities and stockholders' equity		$	311,814			$	318,563

Non-GAAP Financial Measures

To supplement our unaudited condensed consolidated financial statements presented under generally accepted accounting principles in the United States (“GAAP”), we believe certain non-GAAP measures, including adjusted net earnings (loss), and adjusted net earnings (loss) per share, basic and diluted, provide useful information to investors and are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense because this expense is non-cash in nature and we believe excluding this item provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies.

We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

Adjusted Net Earnings (Loss) and Adjusted Net Earnings (Loss) Per Share

Adjusted net earnings (loss) is a non-GAAP financial measure that we define as net earnings (loss) adjusted for stock-based compensation. We believe adjusted net earnings (loss) provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.

Reconciliations of net earnings (loss) to adjusted net earnings (loss) and the presentation of adjusted net earnings (loss) per share, basic and diluted, are as follows:

		Three months ended December 31,								Year ended December 31,
		2025				2024				2025				2024
Common Stock
Numerator:
Net loss available to stockholders, basic and diluted		$	(9,151	)		$	(5,938	)		$	(38,944	)		$	(27,455	)
Add:
Stock-based compensation			7,818				7,282				31,612				24,635
Adjusted net (loss) income available to common stockholders, basic and diluted:		$	(1,333	)		$	1,344			$	(7,332	)		$	(2,820	)
Denominator:
Weighted-average shares outstanding, basic			41,175,725				40,356,756				40,850,739				38,867,726
Weighted-average shares outstanding, diluted			41,175,725				45,622,429				40,850,739				38,867,726
Adjusted net earnings (loss) per share, basic		$	(0.03	)		$	0.03			$	(0.18	)		$	(0.07	)
Adjusted net earnings (loss) per share, diluted		$	(0.03	)		$	0.03			$	(0.18	)		$	(0.07	)

FAQ

How did RxSight (RXST) perform financially in full-year 2025?

RxSight generated 2025 revenue of $134.5 million, down 4% year over year, with gross profit of $103.0 million and a gross margin of 76.6%. Net loss was $38.9 million, or $(0.95) per share, and adjusted net loss was $7.3 million.

What were RxSight (RXST) fourth quarter 2025 results?

In Q4 2025, RxSight reported revenue of $32.6 million, down 19% from Q4 2024. Gross profit was $25.3 million with a 77.5% margin, and net loss totaled $9.2 million, or $(0.22) per share, with adjusted net loss of $1.3 million.

How are RxSight’s Light Adjustable Lens (LAL) and Light Delivery Device (LDD) businesses trending?

In 2025, LAL unit sales rose 12% to 109,615, while LDD system units fell 47% to 163. In Q4 2025, LAL units were 28,611, down 2% year over year, and LDD units were 25, down 70% compared to Q4 2024.

What 2026 financial guidance did RxSight (RXST) provide?

For 2026, RxSight guided to revenue of $120.0–$135.0 million, gross margin of 70%–72%, operating expenses of $150.0–$160.0 million, and non-cash stock-based compensation of $30.0–$32.0 million. The outlook reflects expectations for fewer LDD placements and higher per-unit manufacturing costs.

What is RxSight’s cash position and balance sheet strength at year-end 2025?

As of December 31, 2025, RxSight held $19.9 million in cash and cash equivalents and $208.2 million in short-term investments, totaling $228.1 million. Total assets were $311.8 million, with stockholders’ equity of $275.7 million and total liabilities of $36.1 million.

How did RxSight’s operating expenses and losses change in 2025?

Operating expenses increased to $151.2 million in 2025 from $135.8 million in 2024, driven by commercial, operational, R&D and marketing investments. Net loss widened to $38.9 million from $27.5 million, while adjusted net loss rose to $7.3 million from $2.8 million.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 395.6 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 23.3 KB